Major Pharma Short Interest Remains Mixed, With 1 Massive Drop
The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
The short interest data have been released for the April 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be big upside.
The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
Pfizer Inc. (NYSE: PFE) saw its short interest massively fall to 149.82 million shares from the previous 323.94 million. The previous reading is the highest on the year. Shares of Pfizer closed Tuesday at $33.05, within a 52-week trading range of $28.25 to $36.46.
Merck & Co. Inc. (NYSE: MRK) saw an increase in short interest to 30.40 million shares from 28.66 million in the previous period. Merck shares closed Tuesday at $56.04, in a 52-week range of $45.69 to $61.70.
[recirclink id=328304]
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) short interest increased to 22.40 million shares. The previous level was 18.05 million. The current level is the highest in the past 52 weeks. Shares of Teva closed Tuesday at $55.50, in a 52-week range of $52.62 to $72.31.
Bristol-Myers Squibb Co. (NYSE: BMY) saw its short interest decrease to 21.50 million shares from the previous reading of 22.18 million. Shares closed Tuesday at $70.86, within a 52-week range of $51.82 to $71.07.
AbbVie Inc. (NYSE: ABBV) short interest decreased slightly to 21.76 million shares, compared to the previous level of 22.53 million. Short interest has backed way off its highest level of the past year last May. Shares of AbbVie closed Tuesday at $60.93, in a 52-week trading range of $45.45 to $71.60.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
